Purpose {#S1}
=======

Cervical cancer remains a major global healthcare problem, with 569 847 new cases and 311 365 deaths occurring worldwide each year \[[@ref1]\]. The major burden of this mortality is borne by the lesser-developed regions of the world. In India, it is a source of major morbidity and mortality, with 96 922 new cases occurring annually, and 60 078 women succumbing to this disease. A majority of patients present to the clinic with advanced stages of disease \[[@ref2]\].

Aggressive multi-modality therapy can lead to encouraging outcomes in these patients \[[@ref3]\]. These outcomes are typically achieved in the context of timely, multi-disciplinary care. In locally advanced cervical cancer (LACC), radical radio-chemotherapy with external beam radiotherapy (EBRT), concomitant radio-sensitizing chemotherapy and intra-cavitary brachytherapy (ICBT) with adequate doses and an overall treatment time of 7-8 weeks is vital for disease outcome and toxicities. However, depending on the resource availability, logistics and socio-economic issues especially in low and middle income countries (LMICs), the prevalent practices are heterogeneous and seldom reported. We conducted this online survey with an aim to investigate and understand the patterns of care of cervical cancer brachytherapy in India in terms of scheduling, protocol, imaging used, dose volume prescription and usage of and aspirations regarding future implementation of image-guided brachytherapy (IGBT). The results of the survey form the basis of this report. The survey was conducted under the aegis of the Indian Brachytherapy Society (IBS), a non-profit all-India organization which provides the primary impetus towards improving brachytherapy practice and knowledge in the country \[[@ref4]\] and has recently published comprehensive guidelines related to the management of carcinoma with emphasis on ICBT \[[@ref5]\].

Material and methods {#S2}
====================

The survey was exempt from Institutional Review Board submission. A 17-question online survey was sent via electronic mail to radiation oncologists involved in the treatment of gynecological malignancies at 116 centers in India. The questionnaire included the nature of practice (government vs. private, academic vs. non-academic), caseload of cervical cancers handled every year, distribution of cases, timing of ICBT relative to EBRT, dose fractionation schedules used, usage and type of anesthesia, type of applicators used and type of implants performed, imaging used intra-operatively during insertion and for planning, method of dose prescription and dose constraints used. The responders were also asked regarding the overall treatment times typically achieved during treatment and also as to their desire for implementing 3-dimensional image-based brachytherapy in the near future (see [Table 1](#T1){ref-type="table"}). Respondents were required to have at least 1-year post-residency experience to be eligible. One response per center was deemed as representative of clinical practice at the center. In the case of multiple responses, the responder with the greater experience was chosen. Data were collected from the online survey responses and analyzed using SPSS Version 22 (IBM Corp. Armonk, NY, USA).

###### 

Survey questions

+-----------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Question number | Question                                                                                                                                                                                                                                                                                                                                                                             | Type of response           | Options                                                                                                                                                                                                                                                                                |
+=================+======================================================================================================================================================================================================================================================================================================================================================================================+============================+========================================================================================================================================================================================================================================================================================+
| 1               | Kindly state your name                                                                                                                                                                                                                                                                                                                                                               | Text reply\                | NA                                                                                                                                                                                                                                                                                     |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      | Single response allowed    |                                                                                                                                                                                                                                                                                        |
+-----------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 2               | Kindly mention the name of the institute where you are currently working                                                                                                                                                                                                                                                                                                             | Text reply\                | NA                                                                                                                                                                                                                                                                                     |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      | Single response allowed    |                                                                                                                                                                                                                                                                                        |
+-----------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 3               | Kindly state the nature of your institute                                                                                                                                                                                                                                                                                                                                            | Check box\                 | Government Oncology Centre/Regional Cancer Centre (RCC)Private Oncology CentreMedical College                                                                                                                                                                                          |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      | Single response allowed    |                                                                                                                                                                                                                                                                                        |
+-----------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 4               | Kindly mark your area of expertise                                                                                                                                                                                                                                                                                                                                                   | Check box\                 | Radiation oncologist                                                                                                                                                                                                                                                                   |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      | Single response allowed    |                                                                                                                                                                                                                                                                                        |
+-----------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 5               | Kindly mention the extent of your experience                                                                                                                                                                                                                                                                                                                                         | Check box\                 | 1-5 yrs5-10 yrs10-15 yrs\> 15 yrs                                                                                                                                                                                                                                                      |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      | Single response allowed    |                                                                                                                                                                                                                                                                                        |
+-----------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 6               | What is the stage grouping of cervical cancers that you see at your institute?                                                                                                                                                                                                                                                                                                       | Table\                     | Categorically asked regarding numbers diagnosed per year and numbers treated per year as regards FIGO stages:\                                                                                                                                                                         |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      | Multiple responses allowed | IA-IB2\                                                                                                                                                                                                                                                                                |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      |                            | IIA-IIB\                                                                                                                                                                                                                                                                               |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      |                            | IIIA-IIIB\                                                                                                                                                                                                                                                                             |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      |                            | IVA-IVB                                                                                                                                                                                                                                                                                |
+-----------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 7               | Kindly specify the commonly used/institutional protocol for dose fractionation schedules for external beam radiotherapy (EBRT) and intracavitary brachytherapy (ICBT) in your institute in the table as indicated (Please mention all doses in grays in single digits, e.g. 9 Gy -- please enter as 9, if using decimals, please restrict yourself to a single decimal, e.g. 7.5 Gy) | Table\                     | Asked under headings ofDose of EBRT(Gy)Mid-line shielding used(Yes/No)Midline shielding introduced at (Gy)No of sessions of ICBTDose/session of ICBT(Gy)                                                                                                                               |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      | Multiple responses allowed |                                                                                                                                                                                                                                                                                        |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      |                            | Under stage groupings                                                                                                                                                                                                                                                                  |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      |                            |                                                                                                                                                                                                                                                                                        |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      |                            | IA-IB2IIA-IIBIIIA-IIIB                                                                                                                                                                                                                                                                 |
+-----------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 8               | Please tick the methods for ICBT used in your institute (Please feel free to mark multiple options)\                                                                                                                                                                                                                                                                                 | Check box\                 | Tandem ovoid type applicatorTandem ring type applicatorRing applicator with additional interstitial needles (Vienna type)Tandem ovoid applicator with interstitial needle grooves (Rotterdam type)Tandem/Ring ovoid applicator with additional interstitial templatesNone of the above |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      | Multiple responses allowed |                                                                                                                                                                                                                                                                                        |
+-----------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 9               | In what percentage of cases of advanced cervical cancer are you performing complex interstitial implants?                                                                                                                                                                                                                                                                            | Check box\                 | \< 10%10-30%\> 30%                                                                                                                                                                                                                                                                     |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      | Single response allowed    |                                                                                                                                                                                                                                                                                        |
+-----------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 10              | Kindly specify the method of prescription for ICBT in your institute (Please feel free to mark multiple options)\                                                                                                                                                                                                                                                                    | Check box\                 | Point A basedICRU 60 Gy reference isodoseVolume based prescription (GEC- ESTRO)None of the above                                                                                                                                                                                       |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      | Multiple responses allowed |                                                                                                                                                                                                                                                                                        |
+-----------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 11              | How are you performing ICBT procedures at your institute? (Please feel free to mark multiple options)\                                                                                                                                                                                                                                                                               | Check box\                 | Sedation aloneSedation with local blockSpinal anesthesiaGeneral anesthesiaLocal anesthesiaNone of the above                                                                                                                                                                            |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      | Multiple responses allowed |                                                                                                                                                                                                                                                                                        |
+-----------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 12              | What sort of image guidance do you use to rule out perforation and optimize applicator placement at your institute? (Please feel free to mark multiple options)                                                                                                                                                                                                                      | Check box\                 | USGCTMRINone of the above                                                                                                                                                                                                                                                              |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      | Multiple responses allowed |                                                                                                                                                                                                                                                                                        |
+-----------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 13              | What imaging modalities do you use for planning ICBT in your practice? (Please feel free to mark multiple options)                                                                                                                                                                                                                                                                   | Check box\                 | Orthogonal X raysUSGCTMRINone of the above                                                                                                                                                                                                                                             |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      | Multiple responses allowed |                                                                                                                                                                                                                                                                                        |
+-----------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 14              | What sort of optimization do you use in ICBT planning? (please feel free to mark multiple options)\                                                                                                                                                                                                                                                                                  | Check box\                 | Manual dwell weights and timesGeometrical optimisationGraphical optimisationInverse optimisation (IPSA/HIPO)None of the above                                                                                                                                                          |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      | Multiple responses allowed |                                                                                                                                                                                                                                                                                        |
+-----------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 15              | Kindly specify the dose objectives that you aim to achieve in day-to-day planning of ICBT (Please mention all doses in grays in single digits, e.g. 9 Gy -- please enter as 9, if using decimals, please restrict yourself to a single decimal, e.g. 7.5 Gy)                                                                                                                         | Table with Check boxes\    | Enquired about dose toTarget (HR-CTV, IR-CTV, 60 Gy reference isodose)BladderRectumSigmoid                                                                                                                                                                                             |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      | Multiple responses allowed |                                                                                                                                                                                                                                                                                        |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      |                            | In terms of the following parameters                                                                                                                                                                                                                                                   |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      |                            |                                                                                                                                                                                                                                                                                        |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      |                            | 60 Gy isodose volumeHR CTVIR CTVBladderRectumSigmoid                                                                                                                                                                                                                                   |
+-----------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 16              | If you do not use 3D image based brachytherapy at your institute, when do you plan to institute the same?                                                                                                                                                                                                                                                                            | Check box\                 | Within 6 monthsWithin 1 year1-5 yrs\> 5 yrsNo plans                                                                                                                                                                                                                                    |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      | Single response allowed    |                                                                                                                                                                                                                                                                                        |
+-----------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 17              | What is the overall treatment time that you typically achieve in the radical treatment of cervical cancer\                                                                                                                                                                                                                                                                           | Check box\                 | \< 42 days42-49 days\> 49 days49-56 days\> 56 days                                                                                                                                                                                                                                     |
|                 |                                                                                                                                                                                                                                                                                                                                                                                      | Single response allowed    |                                                                                                                                                                                                                                                                                        |
+-----------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+

Descriptive statistics were used to analyze the responses in terms of frequencies and percentages. For looking at factors determining the use of IGBT the study team first selected certain factors deemed relevant in terms of prognostic significance (experience, type of setup, caseload and percentage of advanced cases seen in clinical practice). All values were dichotomized at the median except experience, which was divided into 5-year intervals to facilitate analysis (experience less than five years and experience less than ten years). Associations with categorical variables (such as experience, type of setup) were tested by the chi square test, while those with continuous variables (such as caseload, percentage of advanced cases seen) were tested by means of the *t*-test.

Results {#S3}
=======

Between January and June 2017, 116 respondents were contacted over e-mail and postal mail. Fifty-nine respondents replied to the survey mail and contributed data for the analysis. The overall response rate was 51% (59/116). Fifty-nine percent (35/59) of respondents were from academic centers (including government medical colleges, private medical colleges with radiotherapy departments with residency courses, and regional and state cancer centers funded by the government), and the remaining 34% (24/59) were from private oncology centers. Eighty-eight percent of respondents (51/59) had more than five years of experience in treating gynecological cancers, and 53% of respondents (30/59) reported more than ten years of experience.

The average number of cases of cervical cancer treated every year was 255 (median: 161 cases, IQR 76-355). The pattern of case presentation was typically dominated by advanced stages (FIGO 2009 stage IB2-IVA), which constituted 87% of the cases seen by respondents in their clinical practice. All respondents used a combination of EBRT and ICBT to treat cervical cancer. EBRT practice was fairly constant, with all centers administering doses ≥ 45 Gy at 1.8-2 Gy per fraction. Sixty-two percent of centers (37/59) performed ICBT after conclusion of EBRT. The usage of midline blocks (MLB) was reported by 20% of centers (12/60). The most common dose fractionation schedule used was 7 Gy per fraction, once weekly for a total of 3-4 applications (74%, 43/59 centers). High-dose-rate (HDR) brachytherapy was the predominant mode of administration of ICBT, with 97% (57/59) of centers reporting its usage. The majority of centers were able to complete treatment within 49-56 days (44%, 26/59 centers), with 10% of centers (6/59 centers) exceeding 56 days.

Centers reported multiple forms of anesthesia usage in the same institute. These included general anesthesia (44%, 26/59 centers), spinal anesthesia (44%, 26/59 centers), and regional anesthesia (27%, 10/59 centers).

Ultrasound (USG) guidance was used for optimizing applicator insertion and placement by 29% of respondents (16/59 centers). Computed tomography (CT) scan was used to check the correctness of applicator placement by 46% of respondents (27/59 centers). One center reported the use of magnetic resonance imaging (MRI) for intra-operative optimization of applicator placement.

Intra-cavitary brachytherapy was predominantly performed using tandem and ovoid (80%, 47/59 centers) and tandem ring (24%, 14/59 centers) applicators. Complex applications (intracavitary with interstitial or interstitial alone, IC + IS/IS only) were being performed by 49% (29/59 centers) in \< 10% of all cases and 15% (9/59 centers) in 10-30% of all cases and by 5% (3/59 centers) in more than 30% of cases. Some form of imaging was performed for planning by 97% (57/59 centers) of respondents, with CT scan (65%, 38/59 centers) and orthogonal X-rays (36%, 21/59 centers) being the most common modalities. MRI-based IGBT was performed by 9% (5/59 centers). Point A based reporting remained the most commonly used form of method for dose volume reporting, with 66% (39/59 centers) using the same. Contemporary dose volume reporting, as mandated by the GEC-ESTRO guidelines \[[@ref6],[@ref7]\], was performed by 36% (21/59 centers) of respondents. Seven percent (4/59 centers) of respondents reported using the 60 Gy reference isodose volume as stipulated by the ICRU-38 \[[@ref8]\]. However, details of target volumes and dose constraints used for organs at risk were poorly reported and no analysis could be done for them.

Plan optimization was performed by a variety of methods, with manual optimization of dwell weights and times being most common (52%, 30/59 centers), followed by geometrical optimization (44%, 26/59 centers). Use of graphical optimization (24%, 14/59 centers) and inverse optimization (12%, 7/59 centers) remains lower.

Overall, 64% of respondents (38/59 centers) reported using some form of IGBT based on cross sectional imaging. In case of non-usage of IGBT, we enquired as to whether there were plans to implement IGBT in the near future, and the tentative time frames for implementing it. There were 24/59 responses; 7% (4/59 centers) replied that they had no plans for implementing IGBT at any time, 17% (10/59 centers) replied that they had plans to introduce IGBT in their clinical practice within the next 1-5 years. One respondent reported plans to implement IGBT within 1 year and 15% (9/59 centers) reported that they had plans of commencing after more than 5 years. A comparison with other surveys is presented in [Table 2](#T2){ref-type="table"}.

###### 

Comparison of surveys

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                                                 ABS 2010\                                                               ABS 2016\                                                                Canadian Survey 2011\            Indian Survey (AIIMS)\              Present Survey (TMH)\
                                                            Vishwanathan *et al*. \[[@ref17]\]                                      Grover *et al*. \[[@ref26]\]                                             Pavamani *et al*. \[[@ref16]\]   Gandhi *et al*. 2015 \[[@ref15]\]   Current study
  --------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------ -------------------------------- ----------------------------------- ----------------------------------------
  No. of potential participants/centers                     256                                                                     370                                                                      58                               202                                 116

  No. of replies valid for analysis                         133                                                                     219                                                                      36                               90                                  59

  Response rate valid for analysis                          51.9%                                                                   59.1%                                                                    62%                              44.5%                               50.8%

  Academic centers participating in the survey              30%                                                                     46%                                                                      100%                             72%                                 54.2%

  Dose rate\*                                               HDR -- 53%\                                                             HDR -- 80%\                                                              HDR -- 68%\                      HDR -- 89%\                         HDR -- 96.6%\
                                                            LDR -- 15%\                                                             LDR -- 3%\                                                               LDR -- 24%\                      LDR -- 13%\                         LDR -- 2.5%\
                                                            Combination (HDR, LDR and PDR alone or in various combination) -- 32%   Combination (HDR, LDR and PDR alone or in various combinations) -- 16%   PDR -- 12%\                      PDR -- 14%\                         PDR -- 0.9%\
                                                                                                                                                                                                             HDR and LDR -- 1.5%\                                                 
                                                                                                                                                                                                             HDR or PDR -- 3%                                                     

  Imaging used for insertion and placement optimization\*   USG -- 56%\                                                             USG -- 32%\                                                              USG -- 35%                       No data                             USG -- 28.8%\
                                                            Fluoroscopy -- 37%\                                                     Fluoroscopy -- 6%\                                                                                                                            CT -- 45.7%\
                                                            CT -- 24%\                                                              CT -- 17%\                                                                                                                                    MRI -- 1 centre
                                                            None -- 20%\                                                            MRI -- 4%                                                                                                                                     
                                                            MRI -- 1 center                                                                                                                                                                                                       

  Imaging used for planning\*                               Orthogonal X rays -- 62%\                                               Orthogonal X rays -- 88%\                                                Orthogonal X rays -- 50%\        Orthogonal X rays -- 56%\           Orthogonal X rays -- 35.6%\
                                                            CT -- 70%\                                                              CT -- 20%\                                                               CT -- 45%\                       CT -- 69%\                          CT -- 64.4%\
                                                            MRI -- 2%                                                               MRI -- 34%                                                               MRI -- 5%                        MRI -- 14%                          MRI -- 8.5%

  Method for dose volume reporting for target\*             Point A -- 76%\                                                         Point A -- 46%\                                                          MRI users\                       No data                             Point A -- 66.1%\
                                                            3D (CTV based) -- 14%\                                                  GEC-ESTRO (HR-CTV) -- 52%                                                GEC-ESTRO -- 100%\                                                   ICRU 38 60 Gy reference isodose -- 7%\
                                                            Both point A and CTV based -- 7%\                                                                                                                CT/MRI users\                                                        GEC-ESTRO -- 35.9%
                                                            Point A and mg/h -- 3%                                                                                                                           Point A -- 50%\                                                      
                                                                                                                                                                                                             GEC-ESTRO -- 44%                                                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

indicates percentages may add up to more than 100, HDR -- high-dose-rate, LDR -- low-dose-rate, PDR -- pulsed-dose-rate

Discussion {#S4}
==========

Radiation therapy including brachytherapy forms an indispensable part of the curative management of LACC \[[@ref9]\]. Even in FIGO stage IIIB-IVA, local control outside the setting of a clinical trial can be as high as 85% \[[@ref10]\], which is unprecedented in locally advanced squamous carcinomas originating at other sites. However, there are several challenges in achieving this, especially in LMICs, including India, in terms of resources, logistics and expertise. For example, there is shortage of radiation therapy units, skilled human resources \[[@ref11]\], and EBRT and brachytherapy units required for timely ICBT and execution of optimal standard treatment protocols \[[@ref12],[@ref13]\]. We undertook this survey with an aim to understand the gaps in radiotherapeutic management of cervical cancers and to capture details related to radiation therapy for cervical cancer in India. An additional important objective was to understand the acceptance and uptake of newer technologies in brachytherapy in the light of emerging evidence on improved outcomes with image-guided brachytherapy in routine clinical practice \[[@ref14]\].

Our survey attained a response rate of 51%, which was higher than a recent survey conducted in an LMIC \[[@ref15]\] setting, but lower than those in an non-LMIC setting \[[@ref16],[@ref17]\]. The majority of our respondents were from academic institutes with a single response from each institution rather than individual physicians. Also, all the respondents in our study are radiation oncologists and experienced in treating a relatively large number of cervical cancer patients annually (median 161 patients). This is an important and somewhat reassuring finding as treatment at academic and high volume centers has been shown to be associated with better outcomes in cervical cancer \[[@ref18],[@ref19],[@ref20]\].

All the respondents reported a near uniform EBRT treatment protocol of 45-50 Gy followed by ICBT schedules most commonly prescribing 7 Gy × 3-4 fractions, mirroring earlier reported practice in India \[[@ref21]\]. Also, the overwhelming majority reported using HDR brachytherapy (97%), which is reflective of changing global practice \[[@ref22]\] and \> 90% completing the treatment within 56 days and 10% exceeding the overall treatment time (OTT). The exceeded OTT is highly likely to directly impact patient outcomes, and probably arises out of a large unmet need for more EBRT and brachytherapy units which has been found to be substantial and accordingly deserves attention \[[@ref13]\]. Approximately two thirds (62%) perform ICBT after completion of EBRT, which is in line with contemporary global practice \[[@ref23]\]. The applicator insertion procedure is usually done under some form of anesthesia. Brachytherapy application is a relatively painful procedure involving pelvic examination, negotiating the utero-cervical canal, cervical canal dilatation and placement of applicators in the upper vagina followed by vaginal packing. To mitigate the resultant pain and discomfort, the brachytherapy procedure is usually done under anesthesia and analgesic cover. Our survey results suggest that the majority of centers perform the brachytherapy procedure under some form of anesthesia, which is encouraging and will likely translate into appropriate placement.

Asymptomatic perforation is a known entity during ICBT, which may not be picked up on routine imaging. As many as 13.7% of insertions, including 8.7% of insertions where the treating radiation oncologist was confident regarding correct tandem placement, were found to harbor perforations on CT imaging \[[@ref24]\]. To minimize the uterine perforation rates use of real-time ultrasonography during the procedure is attractive and implemented in clinical practice \[[@ref25]\]. In our survey, 29% of respondents used USG guidance and 46% of respondents performed CT imaging for optimizing applicator insertion and placement, suggesting some QA for optimizing BT insertions. Advanced BT applications including IC + IS were performed in approximately 30% of cases by only 3 centers (5%) in a setting where locally advanced cervical cancer is seen in more than 2/3 in routine clinical practice. This may be attributed to lack of: (i) advanced BT applicators and (ii) availability of expertise and skills.

Almost all of the respondents (97%) reported use of imaging for brachytherapy planning. Also, the rates of usage of orthogonal X-rays (36%) are lower than previously reported from India \[[@ref12]\] and data from North America published 5-8 years ago \[[@ref17]\], while CT imaging was used by two thirds, which is relatively few as compared to other series \[[@ref26]\]. The use of MR imaging has improved from 2% to 8% since 2007 but is substantially lower than the western reports \[[@ref26]\]. A comparative table between the current survey and similar surveys conducted in the West illustrates these differences in greater detail ([Table 2](#T2){ref-type="table"}).

Despite the relatively good availability and uptake of cross sectional imaging, especially CT, point A based dose prescription remained the most common form of prescription. The ICRU-38 60 Gy reference isodose volume reporting was negligible, reflecting lower acceptability, similar to published literature \[[@ref27]\]. Use of GEC-ESTRO volume-based parameters was performed by 36% of respondents, similar to other reported series \[[@ref26]\]. This suggests that point A prescription is still a preferred method, with approximately one third of respondents using it during the transition from 2D to 3D based parameters.

Although MRI-based dose volume parameters are the gold standard, the major hurdle in the Indian setting is lack of MRI in radiation oncology departments and limited access to MRI in the radiology clinic due to competing indications and long queues. This is also reflected in our survey, with extremely poor reporting of target and organ at risk (OAR) related dose volume parameters and limited optimization utilization even for routine ICBT applications. To mitigate this, there have been attempts for alternatives. A recent publication by Mahantshetty *et al*. showed that using intraoperative trans-rectal ultrasonography (TRUS) and peri-operative CT combined with image information from MRI at diagnosis would lead to target and OAR delineation which was just as robust as gold-standard MRI-based image-based brachytherapy (IBBT) \[[@ref28]\]. Such attractive alternatives would be more beneficial and will be better utilized in Indian and LMIC settings.

Finally, in terms of implementation plans in the near future, approximately one third of the respondents wish to introduce some form of image-based brachytherapy within the next 5 years. The results of a survey conducted 4 years ago amongst participants of an IBS conference identified training as the main hurdle towards practicing brachytherapy and showed resolve towards changing practice patterns after the conference \[[@ref15]\]. This seems to be reflected in the increased uptake of imaging, especially cross sectional imaging in ICBT planning in the results of our survey. The increased resolve of stakeholders in conjunction with the ongoing efforts of various national (AROI, IBS) and international organizations (ESTRO) for dissemination and implementation of IGBT in cervical cancers seems to be reaping rewards. Also, various strategies to motivate economically viable solutions are being reported for increasing viability for potential stakeholders, e.g. a health economic model for MRI-based IGABT approach \[[@ref29]\] and alternative imaging protocols including ultrasonography/CT hybrid combinations \[[@ref28]\]. We believe these efforts will be highly fruitful in due course.

Our survey report has some limitations including relatively low participation rates, inherent bias in terms of responses from possibly motivated institutions/centers, and no detailed questions on the quality indicators of EBRT techniques and chemotherapy. Despite these limitations, the current publication represents patterns of care in cervical cancer as practiced among experienced clinicians with a high caseload in an LMIC setting and is likely to offer useful insights into improving outcomes in cervical cancer in many other similar settings.

Conclusions {#S5}
===========

Our survey results suggest a fairly uniform pattern of radiotherapy treatment for cervical cancer, with EBRT doses of 45-50 Gy and 3-4 fractions of high dose rate ICBT of 7 Gy each with reasonable overall treatment times. There is an increasing trend for use of cross sectional imaging, particularly CT imaging for BT planning with point A prescription/reporting only, while target concept and volume based prescription is still in transition. Finally, the intentions to implement 3D IGBT for cervical cancer are increasing. A follow-up survey after a few years and comparison with the results of the current survey would be useful to evaluate transition/changing practices in brachytherapy for cervical cancers.

The survey was selected for poster presentation at the American Brachytherapy Society (ABS) 2018 conference.
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